CMPP –MINI 2

What is Comprehensive Myeloma Protein Panel (CMPP) Mini 2 test?

Comprehensive Myeloma Protein Panel (CMPP) Mini 2 test typically combines (SFLC) SERUM FREE LIGHT CHAIN KAPPA & LAMBDA RATIO, IMMUNOGLOBULIN (IGG,IGM,IGA), Beta 2-MICROGLOBULIN to assess clonal protein production and disease burden.

Why consider Comprehensive Myeloma Protein Panel (CMPP) Mini 2 test?

Comprehensive Myeloma Protein Panel (CMPP) Mini 2 test primarily used to help diagnose multiple myeloma, a cancer affecting the bone marrow and plasma cells. It can also be used to identify monoclonal gammopathy, which can be a precursor to myeloma or a sign of another plasma cell disorder. It can be used to monitor disease progression, assess the effectiveness of treatment, and detect relapses of myeloma.

Who should get this Comprehensive Myeloma Protein Panel (CMPP) Mini 2 test?

• Individuals showing signs and symptoms such as unexplained bone pain, fatigue, anemia, or frequent infections, which may suggest multiple myeloma or other plasma cell disorders.
• Patients with a confirmed diagnosis of multiple myeloma who are undergoing treatment or need follow-up tests to monitor the disease.
• Individuals at risk due to a family history of hematologic cancers.

More Information about Comprehensive Myeloma Protein Panel (CMPP) Mini 2 test

Other Names - Multiple Myeloma, Myeloma Panel, Comprehensive Myeloma Panel, serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (IFE), quantitative immunoglobulins (IgG, IgA, IgM)

Multiple myeloma (MM) is a type of blood cancer that arises from plasma cells, a type of white blood cell found in the bone marrow. In multiple myeloma, these plasma cells become abnormal (malignant) and multiply uncontrollably, interfering with normal blood cell production and causing various complications.